Show simple item record

dc.contributor.authorStavrinides, V
dc.contributor.authorNorris, JM
dc.contributor.authorKarapanagiotis, S
dc.contributor.authorGiganti, F
dc.contributor.authorGrey, A
dc.contributor.authorTrahearn, N
dc.contributor.authorFreeman, A
dc.contributor.authorHaider, A
dc.contributor.authorCarmona Echeverría, LM
dc.contributor.authorBott, SRJ
dc.contributor.authorBrown, LC
dc.contributor.authorBurns-Cox, N
dc.contributor.authorDudderidge, TJ
dc.contributor.authorEl-Shater Bosaily, A
dc.contributor.authorGhei, M
dc.contributor.authorHenderson, A
dc.contributor.authorHindley, RG
dc.contributor.authorKaplan, RS
dc.contributor.authorOldroyd, R
dc.contributor.authorParker, C
dc.contributor.authorPersad, R
dc.contributor.authorRosario, DJ
dc.contributor.authorShergill, IS
dc.contributor.authorWinkler, M
dc.contributor.authorKirkham, A
dc.contributor.authorPunwani, S
dc.contributor.authorWhitaker, HC
dc.contributor.authorAhmed, HU
dc.contributor.authorEmberton, M
dc.contributor.authorPROMIS Group
dc.coverage.spatialUnited States
dc.date.accessioned2023-03-06T15:50:36Z
dc.date.available2023-03-06T15:50:36Z
dc.date.issued2022-12-13
dc.identifier.citationRadiology, 2022, pp. 220762 -en_US
dc.identifier.issn0033-8419
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5710
dc.identifier.eissn1527-1315
dc.identifier.eissn1527-1315
dc.identifier.doi10.1148/radiol.220762
dc.description.abstractBackground The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose To assess how Gleason grade, maximum cancer core length (MCCL), inflammation, prostatic intraepithelial neoplasia (PIN), or atypical small acinar proliferation within a Barzell zone affects the odds of MRI visibility. Materials and Methods In this secondary analysis of the Prostate MRI Imaging Study (PROMIS; May 2012 to November 2015), consecutive participants who underwent multiparametric MRI followed by a combined biopsy, including 5-mm transperineal mapping (TPM), were evaluated. TPM pathologic findings were reported at the whole-prostate level and for each of 20 Barzell zones per prostate. An expert panel blinded to the pathologic findings reviewed MRI scans and declared which Barzell areas spanned Likert score 3-5 lesions. The relationship of Gleason grade and MCCL to zonal MRI outcome (visible vs nonvisible) was assessed using generalized linear mixed-effects models with random intercepts for individual participants. Inflammation, PIN, and atypical small acinar proliferation were similarly assessed in men who had negative TPM results. Results Overall, 161 men (median age, 62 years [IQR, 11 years]) were evaluated and 3179 Barzell zones were assigned MRI status. Compared with benign areas, the odds of MRI visibility were higher when a zone contained cancer with a Gleason score of 3+4 (odds ratio [OR], 3.1; 95% CI: 1.9, 4.9; P < .001) or Gleason score greater than or equal to 4+3 (OR, 8.7; 95% CI: 4.5, 17.0; P < .001). MCCL also determined visibility (OR, 1.24 per millimeter increase; 95% CI: 1.15, 1.33; P < .001), but odds were lower with each prostate volume doubling (OR, 0.7; 95% CI: 0.5, 0.9). In men who were TPM-negative, the presence of PIN increased the odds of zonal visibility (OR, 3.7; 95% CI: 1.5, 9.1; P = .004). Conclusion An incremental relationship between cancer burden and prostate MRI visibility was observed. Prostatic intraepithelial neoplasia contributed to false-positive MRI findings. ClinicalTrials.gov registration no. NCT01292291 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Harmath in this issue.
dc.formatPrint-Electronic
dc.format.extent220762 -
dc.languageeng
dc.language.isoengen_US
dc.publisherRadiological Society of North America (RSNA)en_US
dc.relation.ispartofRadiology
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectPROMIS Group
dc.titleRegional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-10-25
dc.date.updated2023-03-06T15:44:01Z
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1148/radiol.220762en_US
rioxxterms.licenseref.startdate2022-12-13
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36511804
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1148/radiol.220762
dc.contributor.icrauthorParker, Chris
icr.provenanceDeposited by Mr Arek Surman on 2023-03-06. Deposit type is initial. No. of files: 1. Files: RAD-22-0762.R3_Proof_hi.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record